Most importers discover their HS code during the Bill of Entry, when the goods are already at the port and the demurrage clock is running. The classification decision sets the duty rate, and for research peptides the difference between the right line and the wrong one is significant. This guide gives you the actual structure, the rates that were in force when it was written, and the mistakes that cost money.
The duty stack on a peptide import
Every rupee of import cost on a research peptide consignment is: CIF value → BCD → SWS → IGST. Nothing else applies. There is no AIDC, because AIDC is agricultural-goods only. There is no education cess or CVD, since 2019.
| Layer | Rate for peptides | Base | Notes |
|---|---|---|---|
| Assessable Value (AV) | = CIF | — | Price actually paid or payable, plus freight and insurance to the port of importation. Post-importation inland freight is deductible if shown separately. |
| BCD (Basic Customs Duty) | 7.5% for Chapter 2937 lines | AV | First Schedule. This is the only permanent cost. |
| SWS (Social Welfare Surcharge) | 10% of BCD (= 0.75% of AV) | BCD + AIDC | Tariff Act s.110. Not 10% of total duty. |
| IGST | 18% for Ch. 29 chemicals | AV + BCD + SWS | Creditable ITC if you are GST-registered; refundable against zero-rated exports. |
| Customs handling | approx. ₹400–500 per BoE | — | Trivial per unit, but it is per shipment, so it matters on small test lots. |
The three numbers that matter
| Measure | Chapter 29 chemical (research peptide) | 3004 90 99 (medicament) |
|---|---|---|
| BCD | 7.5% | 10% |
| SWS | 0.75% | 1.0% |
| IGST | 18% | 5% |
| Cash landed (incl. IGST) | ≈ 27.7% over CIF | ≈ 16.6% over CIF |
| Permanent cost (BCD + SWS) | 8.25% of CIF | 11% of CIF |
| IGST cash blocked | 19.5% of CIF (refundable) | 5.5% of CIF |
Read that correctly, because it is counter-intuitive. Chapter 30 looks cheaper because medicaments received a GST cut from 12% to 5% in September 2025 while APIs stayed at 18%. But BCD is not recoverable and IGST is. So for anything that is not a licensed medicament, Chapter 29 at 8.25% permanent beats Chapter 30 at 11% permanent, and it blocks far less working capital.
HS classification for research peptides
Group 1 — polypeptide and protein hormones → 2937 19 00 (and 2937 11 00 for HGH) — BCD 7.5%
Somatotropin (recombinant HGH), tesamorelin, ipamorelin, CJC-1295 without DAC, IGF-1 LR3, kisspeptin-10, PT-141 (bremelanotide), semax (ACTH 4-10 analogue), oxytocin acetate, and thymosin alpha-1 all fall under 2937 19 00, with recombinant HGH under 2937 11 00.
Group 2 — non-hormone research peptides → 2937 90 90 — BCD 7.5%
BPC-157, TB-500, GHK-Cu, KPV, selank, DSIP, SS-31 (elamipretide), thymalin, VIP, MOTS-c, epitalon, pinealon, PEG-MGF and melanotan II all sit under 2937 90 90.
Group 3 — co-lyophilised blends → 2937 90 90 — BCD 7.5%
A blend of BPC-157 + TB-500 + GHK-Cu + KPV, or a two- and three-peptide blend, should be declared as a chemical preparation under 2937 90 90.
Group 4 — small molecules sold alongside peptides
These are not peptides and must not be declared as such. 5-amino-1MQ, L-carnitine and NAD+ each have their own classification, and declaring them under 2937 to obtain the peptide rate is a misdeclaration with penalties under s.114AA of the Customs Act.
Group 5 — pharmaceutical reference standards → 2852 / 3822 at 5%
Notification 45/2025-Customs, TABLE I, S.No. 112 sets BCD at 5% for chapters 2852 and 3822 under the description "Pharmaceutical Reference Standard", extended to 31 March 2028 by the Finance Act 2026. Two conditions apply: the importer must produce a certificate of the reference standard, and the organisation from which it is imported must be approved by WHO or an international standards organisation.
That is 5% BCD plus 0.5% SWS — 5.5% permanent, which is 2.75 points cheaper than a peptide line and a cleaner story for lab customers buying standards.
A worked example
A consignment of USD 20,000 CIF research peptides from China arriving at Nhava Sheva, at ₹83 per USD:
- AV = ₹16,60,000
- BCD @ 7.5% = ₹1,24,500
- SWS @ 10% of BCD = ₹12,450
- IGST base = ₹17,96,950; IGST @ 18% = ₹3,23,451
- Total cash out = ₹21,20,401 (27.7% over CIF)
- Permanent cost if sold domestically = ₹1,36,950 (8.25%)
- Permanent cost if sold for export = ₹1,36,950 (8.25%) — IGST becomes refundable ITC
Declared into 3004 90 99 instead, the same consignment attracts BCD 10% plus SWS 1% — a permanent cost of 11%, roughly ₹45,650 worse, and it drags your research-only SKUs into medicament labelling territory.
How to reduce the duty legitimately
- Source domestically where a domestic plant exists. This is the single biggest lever — 0% duty, 0% IGST, no Bill of Entry, no demurrage, no classification dispute. Price your supplier scorecard on landed cost, not FOB price.
- Use a preferential trade agreement where the rules of origin genuinely qualify. There is no India–China FTA, so Chinese-origin material pays full MFN. But agreements with Korea, EFTA (Switzerland, Norway, Iceland, Liechtenstein), the GCC, ASEAN, the UK, Israel, Australia, Mauritius and Sri Lanka each have their own Chapter 29 schedules, and some may be zero. The gate is substantial transformation plus a valid Certificate of Origin — a China-made peptide shipped from a UAE or Singapore supplier does not qualify.
- Use the SEZ route where it genuinely applies. Notification 11/2026-Customs (in force 1 April 2026 to 31 March 2027) gives concessional BCD on goods manufactured by a qualifying SEZ unit and cleared to the Domestic Tariff Area — 7.5% becomes 6.5% for Chapter 29. The conditions are strict: the SEZ unit must have commenced production on or before 31 March 2025, at least 20% value addition, DTA sales capped at 30% of peak export FOB, no duty drawback on inputs, and a Development Commissioner's certificate.
- Use a bonded warehouse or EOU. Import duty-free, do test batches, repack and label in bond, and pay duty only when you actually clear for domestic sale. No three-year SEZ lock-in and no value-add test.
- Neutralise duty on export-bound stock. IGST at 18% is recoverable. The real cost of an export-bound pallet is 8.25%, not 27.7% — the rest is a timing cost. Advance Authorisation removes the 8.25% upfront and the IGST cash cycle entirely, and is the right fit for an import-and-export operation.
- Apply the reference-standard rate where it genuinely applies. 5% instead of 7.5% on every standards import.
Documents the importer must have ready
- Commercial invoice showing the CAS number and IUPAC name, as required by CBIC Circulars 15/2023 and 23/2023
- Purchase order and proforma invoice
- Bill of Entry with the correct HS code and correct description
- Certificate of Analysis for the lot
- MSDS
- Certificate of Origin where a preferential rate is claimed
- IEC, and the drug licence where the buyer is a licensed trade purchaser
- Shipping bill, airway bill or bill of lading, and the arrival manifest
For the export side of the same question, see our country guides for the United States, the United Kingdom and the European Union, and for the documents we issue with every shipment, see export documentation.